Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiodarone versus beta blockers for new-onset atrial fibrillation in critically ill adults
ISRCTN59775011Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of amiodarone and carvedilol in Atrial fibrillation (AFib) (2 arms), sponsored by University of Birmingham. Primary endpoint: 90-day mortality. Started May 2024; status: recruiting.
02
Drugs
amiodaronecarvedilol
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ISRCTN59775011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN59775011.